T. Rowe Price Investment Management
JANX icon

T. Rowe Price Investment Management’s Janux Therapeutics JANX Stock Holding History

T. Rowe Price Investment Management’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,726
Closed -$24K – 799
2025
Q4 		$24K Sell
1,726
-970,965
-100% -$22.8M ﹤0.01% 682
2025
Q3 		$23.8M Buy
+972,691
New +$23.7M 0.01% 485

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Investment Management's JANX Position: Q1 2026 in Review

T. Rowe Price Investment Management sold out of Janux Therapeutics (JANX) in Q1 2026, closing a stake of 1,726 shares — an estimated $24K sold.

T. Rowe Price Investment Management first reported a position in JANX in Q3 2025 and held it in 2 quarters. The position peaked at $23.8M in Q3 2025. 190 funds tracked by Wall St. Rank hold JANX as of Q1 2026.

  • T. Rowe Price Investment Management reported no remaining Janux Therapeutics position as of Q1 2026 after selling out during the quarter.
  • T. Rowe Price Investment Management sold 1,726 Janux Therapeutics shares in Q1 2026, an estimated $24K.
  • T. Rowe Price Investment Management first reported a position in Janux Therapeutics in Q3 2025 and held it in 2 quarters.
  • T. Rowe Price Investment Management's Janux Therapeutics position peaked at $23.8M in Q3 2025.
  • 190 funds tracked by Wall St. Rank held Janux Therapeutics as of Q1 2026.

Based on T. Rowe Price Investment Management's 13F filing for Q1 2026, filed 15 May 2026.